Production (Stage)
Compass Therapeutics, Inc.
CMPX
$2.38
-$0.03-1.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.19% | 23.54% | 18.96% | 17.37% | 3.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.31% | 14.12% | 17.62% | 15.35% | 20.92% |
| Operating Income | -15.72% | -12.43% | -15.85% | -13.60% | -20.92% |
| Income Before Tax | -21.52% | -16.20% | -17.42% | -10.68% | -13.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.52% | -16.20% | -17.42% | -10.68% | -13.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.52% | -16.20% | -17.42% | -10.68% | -13.89% |
| EBIT | -15.72% | -12.43% | -15.85% | -13.60% | -20.92% |
| EBITDA | -16.07% | -12.83% | -16.36% | -14.11% | -21.66% |
| EPS Basic | -12.72% | -6.19% | -9.42% | 2.00% | 2.33% |
| Normalized Basic EPS | -12.71% | -6.18% | -9.43% | 1.95% | 2.50% |
| EPS Diluted | -12.72% | -6.19% | -9.42% | 2.00% | 2.33% |
| Normalized Diluted EPS | -12.71% | -6.18% | -9.43% | 1.95% | 2.50% |
| Average Basic Shares Outstanding | 7.28% | 9.14% | 7.51% | 11.39% | 15.41% |
| Average Diluted Shares Outstanding | 7.28% | 9.14% | 7.51% | 11.39% | 15.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |